Therapies for interstitial lung disease: past, present and future.
Therapies for interstitial lung disease: past, present and future.
复制标题
DOI：
10.1177/1753465808096948
复制
发表时间：
2008-10-01
影响因子：
4.3
通讯作者：
Meyer, Keith C
中科院分区：
文献类型：
--
作者：
Kim, Robert;Meyer, Keith C
随着我们对各种形式的间质性肺病（ILD）的病理生物学和自然病程的认识不断发展，我们治疗这组异质性肺病的方法也在不断演变。用于治疗各种形式ILD的最早的药物是皮质类固醇，目前皮质类固醇是许多形式ILD治疗的主要手段。然而，很明显，皮质类固醇和其他抗炎药物对许多形式的ILD缺乏疗效，比如特发性肺纤维化（IPF），而且临床试验中的新型疗法针对的是各种形式的纤维化肺病中存在的纤维化过程和/或继发性肺动脉高压（PH）。随着新的研究开展和临床试验进行，新的疗法，比如生物制剂（抗体和细胞周期抑制剂）的使用或干细胞疗法无疑将会不断发展。肺移植仍然是晚期肺病的一种选择，这些晚期肺病呈进行性发展且对非手术疗法无反应。
As our understanding of the pathobiology and natural history of the various forms of interstitial lung disease (ILD) has evolved, so have our approaches to treating this heterogeneous group of lung disorders. The earliest pharmacologic agents used to treat various forms of ILD were corticosteroids, and corticosteroids are currently the mainstay of therapy for many forms of ILD. However, it has become clear that corticosteroids and other anti-inflammatory agents lack efficacy for many forms of ILD, such as idiopathic pulmonary fibrosis (IPF), and newer therapies that are in clinical trials target the fibrogenic process and/or secondary pulmonary hypertension (PH) that is present in various forms of fibrotic lung disease. Novel therapies, such as the use of biologic agents (antibodies and cell cycle inhibitors) or stem cell therapies will undoubtedly evolve as new research is performed and clinical trials are undertaken. Lung transplantation remains an option for advanced lung disease that is progressive and unresponsive to non-surgical therapies.